Trial · NCT02083926
Ketamine Infusion for Social Anxiety Disorder
NCT02083926, Early phase 1, Completed, Yale University; results first posted 2021-03-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ketamine Infusion for Social Anxiety Disorder. Trials, record NCT02083926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02083926
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ketamine Infusion for Social Anxiety Disorder
- NCT number
- NCT02083926
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Social Anxiety Disorder
- Interventions
- Ketamine, Saline
- First posted
- 2014-03-11
- Last updated
- 2021-03-18
- Results first posted
- 2021-03-18
- Limitations and caveats
A significant limitation of our study was that 17 of 18 subjects correctly identified when they received ketamine, suggesting that the use of saline as a placebo control for ketamine led to inadequate blinding.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) | Day 1 (1+28) | Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks. We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion. |
| Primary | Liebowitz Social Anxiety Score (LSAS) | Day 1 (1+28) | Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable \>90= SAD highly probable |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) | Day 1 (1+28) | units on a scale | MEAN | |
| PRIMARY | Liebowitz Social Anxiety Score (LSAS) | Day 1 (1+28) | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) | Ketamine Infusion on Day 0 or Day 28 | 12.1 | Standard Deviation 18.6 | units on a scale | |
| Visual Analogue Scale for Anxiety Symptoms (VAS-anxiety) | Saline Infusion on Day 0 or Day 28 | 19.6 | Standard Deviation 18.5 | units on a scale | |
| Liebowitz Social Anxiety Score (LSAS) | Ketamine Infusion on Day 0 or Day 28 | 66.1 | Standard Deviation 30.9 | score on a scale | |
| Liebowitz Social Anxiety Score (LSAS) | Saline Infusion on Day 0 or Day 28 | 86.1 | Standard Deviation 30 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ketamine Infusion on Day 0, Saline Infusion on Day 28 | 9 | |
| Overall Study | STARTED | Saline Infusion on Day 0, Ketamine Infusion on Day 28 | 9 | |
| Overall Study | COMPLETED | Ketamine Infusion on Day 0, Saline Infusion on Day 28 | 8 | |
| Overall Study | COMPLETED | Saline Infusion on Day 0, Ketamine Infusion on Day 28 | 9 | |
| Overall Study | NOT COMPLETED | Ketamine Infusion on Day 0, Saline Infusion on Day 28 | 1 | |
| Overall Study | NOT COMPLETED | Saline Infusion on Day 0, Ketamine Infusion on Day 28 | 0 |
Source ClinicalTrials.gov
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | things seem to be moving | Nervous system disorders | Ketamine Infusion on Day 0 or Day 28 | 7 | 18 | 7 |
| other | things seem to be moving | Nervous system disorders | Saline Infusion on Day 0 or Day 28 | 2 | 17 | 2 |
| other | things seem unreal | Nervous system disorders | Ketamine Infusion on Day 0 or Day 28 | 9 | 18 | 9 |
| other | things seem unreal | Nervous system disorders | Saline Infusion on Day 0 or Day 28 | 3 | 17 | 3 |
| other | feel like you are separated from reality | Nervous system disorders | Ketamine Infusion on Day 0 or Day 28 | 3 | 18 | 3 |
| other | feel like you are separated from reality | Nervous system disorders | Saline Infusion on Day 0 or Day 28 | 1 | 17 | 1 |
| other | looking at things outside of your body | Nervous system disorders | Ketamine Infusion on Day 0 or Day 28 | 4 | 18 | 4 |
| other | looking at things outside of your body | Nervous system disorders | Saline Infusion on Day 0 or Day 28 | 0 | 17 | 0 |
| other | Feel like a spectator | Nervous system disorders | Ketamine Infusion on Day 0 or Day 28 | 7 | 18 | 7 |
| other | Feel like a spectator | Nervous system disorders | Saline Infusion on Day 0 or Day 28 | 2 | 17 | 2 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ketamine Infusion on Day 0 or Day 28 | 0 | 18 |
| Total, all-cause mortality | Saline Infusion on Day 0 or Day 28 | 0 | 17 |
| Total, other adverse events | Ketamine Infusion on Day 0 or Day 28 | 15 | 18 |
| Total, other adverse events | Saline Infusion on Day 0 or Day 28 | 4 | 17 |
| Total, serious adverse events | Ketamine Infusion on Day 0 or Day 28 | 0 | 18 |
| Total, serious adverse events | Saline Infusion on Day 0 or Day 28 | 0 | 17 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 vs Saline Infusion on Day 0 or Day 28: deaths from any cause | Trial comparisons |
| Ketamine Infusion on Day 0 or Day 28 vs Saline Infusion on Day 0 or Day 28: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02083926
GET https://conductscience.org/api/trials/v1/NCT02083926/events?page=2